CN114504578A - 治疗、预防由病毒感染引起的相关疾病的药物及其用途 - Google Patents
治疗、预防由病毒感染引起的相关疾病的药物及其用途 Download PDFInfo
- Publication number
- CN114504578A CN114504578A CN202210205921.6A CN202210205921A CN114504578A CN 114504578 A CN114504578 A CN 114504578A CN 202210205921 A CN202210205921 A CN 202210205921A CN 114504578 A CN114504578 A CN 114504578A
- Authority
- CN
- China
- Prior art keywords
- days
- virus
- mutant
- coronavirus
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 59
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 45
- 201000010099 disease Diseases 0.000 title claims abstract description 35
- 230000009385 viral infection Effects 0.000 title claims abstract description 20
- 229940079593 drug Drugs 0.000 title claims description 34
- 150000003839 salts Chemical class 0.000 claims abstract description 39
- 229940127073 nucleoside analogue Drugs 0.000 claims abstract description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 33
- 239000002777 nucleoside Substances 0.000 claims description 32
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 32
- 241000711573 Coronaviridae Species 0.000 claims description 28
- 208000024891 symptom Diseases 0.000 claims description 24
- 241000700605 Viruses Species 0.000 claims description 21
- 241001678559 COVID-19 virus Species 0.000 claims description 20
- 206010035664 Pneumonia Diseases 0.000 claims description 18
- 208000015181 infectious disease Diseases 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 17
- 241001135549 Porcine epidemic diarrhea virus Species 0.000 claims description 15
- 201000009240 nasopharyngitis Diseases 0.000 claims description 15
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 claims description 14
- 241001115402 Ebolavirus Species 0.000 claims description 13
- 241000711549 Hepacivirus C Species 0.000 claims description 13
- 241000725619 Dengue virus Species 0.000 claims description 12
- 241001115401 Marburgvirus Species 0.000 claims description 12
- 208000036142 Viral infection Diseases 0.000 claims description 11
- 208000025721 COVID-19 Diseases 0.000 claims description 10
- 241000282414 Homo sapiens Species 0.000 claims description 10
- 206010057190 Respiratory tract infections Diseases 0.000 claims description 10
- 244000309467 Human Coronavirus Species 0.000 claims description 9
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 9
- 241000315672 SARS coronavirus Species 0.000 claims description 9
- -1 amino Chemical group 0.000 claims description 9
- 206010022000 influenza Diseases 0.000 claims description 9
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 8
- 241000712461 unidentified influenza virus Species 0.000 claims description 8
- 239000002671 adjuvant Substances 0.000 claims description 7
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 6
- 241000711467 Human coronavirus 229E Species 0.000 claims description 6
- 241000482741 Human coronavirus NL63 Species 0.000 claims description 6
- 241001428935 Human coronavirus OC43 Species 0.000 claims description 6
- 241000711920 Human orthopneumovirus Species 0.000 claims description 6
- 241000907316 Zika virus Species 0.000 claims description 6
- 208000020329 Zika virus infectious disease Diseases 0.000 claims description 6
- 229910052805 deuterium Inorganic materials 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 210000002784 stomach Anatomy 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 238000011321 prophylaxis Methods 0.000 claims description 4
- 208000006154 Chronic hepatitis C Diseases 0.000 claims description 3
- 208000001528 Coronaviridae Infections Diseases 0.000 claims description 3
- 208000001490 Dengue Diseases 0.000 claims description 3
- 206010012310 Dengue fever Diseases 0.000 claims description 3
- 206010012735 Diarrhoea Diseases 0.000 claims description 3
- 241000711950 Filoviridae Species 0.000 claims description 3
- 241000710781 Flaviviridae Species 0.000 claims description 3
- 206010061192 Haemorrhagic fever Diseases 0.000 claims description 3
- 208000005176 Hepatitis C Diseases 0.000 claims description 3
- 208000025729 dengue disease Diseases 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 208000010710 hepatitis C virus infection Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 239000012458 free base Substances 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 6
- 230000000840 anti-viral effect Effects 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 description 20
- 238000000034 method Methods 0.000 description 16
- 235000012054 meals Nutrition 0.000 description 15
- 239000008280 blood Substances 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 239000000902 placebo Substances 0.000 description 12
- 229940068196 placebo Drugs 0.000 description 12
- 239000003826 tablet Substances 0.000 description 12
- 208000035475 disorder Diseases 0.000 description 10
- 238000012216 screening Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 230000002411 adverse Effects 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 208000035473 Communicable disease Diseases 0.000 description 7
- 235000020937 fasting conditions Nutrition 0.000 description 6
- 239000002207 metabolite Substances 0.000 description 6
- 230000000291 postprandial effect Effects 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 235000020931 dietary conditions Nutrition 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000002485 urinary effect Effects 0.000 description 5
- 206010067484 Adverse reaction Diseases 0.000 description 4
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 4
- 108010082126 Alanine transaminase Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000282887 Suidae Species 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 235000009200 high fat diet Nutrition 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000001174 ascending effect Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 235000021590 normal diet Nutrition 0.000 description 3
- 238000009520 phase I clinical trial Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 206010003671 Atrioventricular Block Diseases 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000013066 combination product Substances 0.000 description 2
- 229940127555 combination product Drugs 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 231100000279 safety data Toxicity 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 208000026425 severe pneumonia Diseases 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- 108010055851 Acetylglucosaminidase Proteins 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 206010003598 Atelectasis Diseases 0.000 description 1
- 241000008904 Betacoronavirus Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000288673 Chiroptera Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011509 Crystalluria Diseases 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010053156 Musculoskeletal discomfort Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 102100030122 Protein O-GlcNAcase Human genes 0.000 description 1
- 208000007123 Pulmonary Atelectasis Diseases 0.000 description 1
- 206010056342 Pulmonary mass Diseases 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010062106 Respiratory tract infection viral Diseases 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- 206010040741 Sinus bradycardia Diseases 0.000 description 1
- 241000589884 Treponema pallidum Species 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000011976 chest X-ray Methods 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 231100000313 clinical toxicology Toxicity 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- ZCGNOVWYSGBHAU-UHFFFAOYSA-N favipiravir Chemical compound NC(=O)C1=NC(F)=CNC1=O ZCGNOVWYSGBHAU-UHFFFAOYSA-N 0.000 description 1
- 229950008454 favipiravir Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 230000009246 food effect Effects 0.000 description 1
- 235000021471 food effect Nutrition 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 208000011140 intestinal infectious disease Diseases 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000036391 respiratory frequency Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Description
Claims (17)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210205921.6A CN114504578A (zh) | 2022-03-03 | 2022-03-03 | 治疗、预防由病毒感染引起的相关疾病的药物及其用途 |
PCT/CN2023/079315 WO2023165566A1 (zh) | 2022-03-03 | 2023-03-02 | 治疗、预防由病毒感染引起的相关疾病的药物及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210205921.6A CN114504578A (zh) | 2022-03-03 | 2022-03-03 | 治疗、预防由病毒感染引起的相关疾病的药物及其用途 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202410177641.8A Division CN118021821A (zh) | 2022-03-03 | 治疗、预防由病毒感染引起的相关疾病的药物及其用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114504578A true CN114504578A (zh) | 2022-05-17 |
Family
ID=81553727
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210205921.6A Pending CN114504578A (zh) | 2022-03-03 | 2022-03-03 | 治疗、预防由病毒感染引起的相关疾病的药物及其用途 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN114504578A (zh) |
WO (1) | WO2023165566A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023165566A1 (zh) * | 2022-03-03 | 2023-09-07 | 苏州旺山旺水生物医药有限公司 | 治疗、预防由病毒感染引起的相关疾病的药物及其用途 |
WO2024051793A1 (en) * | 2022-09-09 | 2024-03-14 | Shanghai Vinnerna Biosciences Co., Ltd. | METHODS ANS KITS FOR TREATING SARS-CoV-2 INFECTION |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112661801A (zh) * | 2020-12-18 | 2021-04-16 | 成都阿奇生物医药科技有限公司 | 一种核苷类似物及其氘代物及其制备方法和用途 |
CN112778310A (zh) * | 2020-04-20 | 2021-05-11 | 中国科学院上海药物研究所 | 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用 |
CN113304166A (zh) * | 2020-02-27 | 2021-08-27 | 河南真实生物科技有限公司 | 核苷类化合物在治疗冠状病毒感染性疾病中的用途 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111961057A (zh) * | 2020-05-26 | 2020-11-20 | 李小冬 | 一种α构型核苷及其在治疗猫冠状病毒感染的应用 |
CN114504578A (zh) * | 2022-03-03 | 2022-05-17 | 苏州旺山旺水生物医药有限公司 | 治疗、预防由病毒感染引起的相关疾病的药物及其用途 |
-
2022
- 2022-03-03 CN CN202210205921.6A patent/CN114504578A/zh active Pending
-
2023
- 2023-03-02 WO PCT/CN2023/079315 patent/WO2023165566A1/zh unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113304166A (zh) * | 2020-02-27 | 2021-08-27 | 河南真实生物科技有限公司 | 核苷类化合物在治疗冠状病毒感染性疾病中的用途 |
CN112778310A (zh) * | 2020-04-20 | 2021-05-11 | 中国科学院上海药物研究所 | 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用 |
WO2021213288A1 (zh) * | 2020-04-20 | 2021-10-28 | 中国科学院上海药物研究所 | 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用 |
CN112661801A (zh) * | 2020-12-18 | 2021-04-16 | 成都阿奇生物医药科技有限公司 | 一种核苷类似物及其氘代物及其制备方法和用途 |
Non-Patent Citations (1)
Title |
---|
DAIBAO WEI等: "Potency and pharmacokinetics of GS-441524 derivatives against SARS-CoV-2" * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023165566A1 (zh) * | 2022-03-03 | 2023-09-07 | 苏州旺山旺水生物医药有限公司 | 治疗、预防由病毒感染引起的相关疾病的药物及其用途 |
WO2024051793A1 (en) * | 2022-09-09 | 2024-03-14 | Shanghai Vinnerna Biosciences Co., Ltd. | METHODS ANS KITS FOR TREATING SARS-CoV-2 INFECTION |
Also Published As
Publication number | Publication date |
---|---|
WO2023165566A1 (zh) | 2023-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Fabiano et al. | Paediatric pharmacology: remember the excipients | |
WO2023165566A1 (zh) | 治疗、预防由病毒感染引起的相关疾病的药物及其用途 | |
KR101801864B1 (ko) | 인플루엔자, 감기 및 염증의 치료에서 레보세티리진 및 몬테루카스트의 용도 | |
US20030143293A1 (en) | Compositions and methods for treating diarrhea | |
WO2013051728A1 (ja) | 睡眠の質改善剤 | |
Teeratakulpisarn et al. | Efficacy of dexamethasone injection for acute bronchiolitis in hospitalized children: a randomized, double‐blind, placebo‐controlled trial | |
US20210330622A1 (en) | Viral infection treatment with 5-aminolevulinic acid | |
WO2021207325A1 (en) | Natural extract and their components for use in mitigating acute respiratory distress syndrome | |
Blair | Remdesivir: a review in COVID-19 | |
Li et al. | A double-blind, randomized, placebo-controlled multicenter study of oseltamivir phosphate for treatment of influenza infection in China | |
US11826331B2 (en) | Capric acid and myristic acid compositions for treating conditions | |
US20060084683A1 (en) | Method for preventing the onset of asthma | |
CN118021821A (zh) | 治疗、预防由病毒感染引起的相关疾病的药物及其用途 | |
AU2022203621A1 (en) | Use of cyanobacterial biomass in treating hepatitis b virus infection | |
US20230190652A1 (en) | Composition for the treatment of covid-19 and treatment method | |
AU749169B2 (en) | A method for preventing the onset of asthma | |
JP2002515035A (ja) | アミノステロール化合物の治療学的使用 | |
WO2021217702A1 (zh) | 一种预防或治疗covid-19新冠肺炎的药物、食物及其应用 | |
RU2286770C2 (ru) | Антигриппозное средство | |
Kim | Antiviral drugs | |
WO2019108319A1 (en) | Compositions containing euglena gracilis for viral protection and related methods | |
US20230149328A1 (en) | Method for Treating SARS and Treating or Preventing ARDS | |
TW202126297A (zh) | 肌肉量之降低抑制、降低預防、維持、回復或增加用組成物 | |
Bandyopadhyay et al. | Systemic Review Article | |
CN113952330A (zh) | 草棉黄素在制备治疗鼻炎的药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20221201 Address after: 215123 floor 8, building a, No. 108, Yuxin Road, Suzhou Industrial Park, Jiangsu Province Applicant after: SUZHOU VIGONVITA LIFE SCIENCES Co.,Ltd. Applicant after: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES Applicant after: Wuhan Institute of Virology, Chinese Academy of Sciences Address before: 215123 floor 8, building a, No. 108, Yuxin Road, Suzhou Industrial Park, Jiangsu Province Applicant before: SUZHOU VIGONVITA LIFE SCIENCES Co.,Ltd. |
|
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Country or region after: China Address after: 215123 floor 8, building a, No. 108, Yuxin Road, Suzhou Industrial Park, Jiangsu Province Applicant after: Suzhou Wangshan Wangshui Biopharmaceutical Co.,Ltd. Applicant after: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES Applicant after: Wuhan Institute of Virology, Chinese Academy of Sciences Address before: 215123 floor 8, building a, No. 108, Yuxin Road, Suzhou Industrial Park, Jiangsu Province Applicant before: SUZHOU VIGONVITA LIFE SCIENCES Co.,Ltd. Country or region before: China Applicant before: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES Applicant before: Wuhan Institute of Virology, Chinese Academy of Sciences |